# US 2026/0284184 A1 · Biodegradable scaffolds for enhancing vaccine efficacy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0284184 A1
- Document ID: US20260284184A1
- Status: Published application
- Kind: A1
- Application number: 19/474,126
- Filed: 2024-04-10
- Published: 2026-09-24
- Earliest claimed: 2023-04-11
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Nisarg Shah; Matthew Kerr
- Web page: https://patentgrep.com/patent/US20260284184A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 37/04: Immunostimulants
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- A61K 2039/876: {Skin, melanoma}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Scaffolds and materials which provide for sustained release of vaccine components upon delivery to a subject, thus resulting enhanced immune response compared to bolus vaccination strategies.

## Claims

### Claim 1

A sustained release vaccine composition, comprising:
(a) a biodegradable scaffold;
(b) an antigen; and
(c) an adjuvant;
wherein the antigen and adjuvant are disposed within the biodegradable scaffold, and wherein degradation of the biodegradable scaffold results in release of the antigen and the adjuvant from the biodegradable scaffold.

### Claim 2 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the antigen and adjuvant are released in a burst phase and a sustained release phase.

### Claim 3 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the biodegradable scaffold is comprised of hyaluronic acid polymers.

### Claim 4 (depends on 3)

The sustained release vaccine composition of claim 3, wherein the hyaluronic acid polymers have a molecular weight of about 0.1 MDa to about 10 MDa.

### Claim 5 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the biodegradable scaffold is porous and has an average pore size of from about 20 micron to about 200 micron.

### Claim 6 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the biodegradable scaffold is a hydrogel.

### Claim 7 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the adjuvant is a TLR9 agonist.

### Claim 8 (depends on 7)

The sustained release vaccine composition of claim 7, wherein the TLR9 agonist is a CpG oligonucleotide.

### Claim 9 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the adjuvant is a dendritic cell maturation factor.

### Claim 10 (depends on 9)

The sustained release vaccine composition of claim 9, wherein the dendritic cell maturation factor GM-CSF.

### Claim 11 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the antigen is a tumor-associated antigen.

### Claim 12 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the antigen is a pathogen-associated antigen.

### Claim 13 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the composition has a degradation-half life in vivo of at least two weeks.

### Claim 14 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the composition releases the antigen and/or the adjuvant in vivo for a period of at least one week.

### Claim 15 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the composition is infiltrated by one or more immune cells following administration to a subject.

### Claim 16 (depends on 15)

The sustained release vaccine composition of claim 15, wherein the one or more immune cells comprise a lower proportion of monocytes compared to a corresponding composition without the adjuvant.

### Claim 17 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the composition does not elicit inflammation associated with foreign body response upon administration to a subject.

### Claim 18 (depends on 1)

The sustained release vaccine composition of claim 1, wherein the composition elicits a greater antibody response upon administration to a subject compared to a corresponding composition without the adjuvant.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the sustained release vaccine composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the pharmaceutical composition is formulated for subcutaneous administration.

### Claim 21 (depends on 1)

A method of performing a vaccination in a subject, the method comprising administering to the subject the sustained release vaccine composition of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the sustained release vaccine composition is administered subcutaneously.

### Claim 23 (depends on 21)

The method of claim 21, wherein the administering the sustained release vaccine composition comprises administering a prime and a boost dose of the sustained release vaccine composition.

### Claim 24

A method of preparing a sustained release vaccine composition, comprising: crosslinking at a temperature below 0° C. a plurality of biodegradable polymers in the presence of an antigen and an adjuvant to provide a biodegradable scaffold with the antigen and adjuvant disposed therein.

### Claim 25 (depends on 24)

The method of claim 24, wherein the biodegradable scaffold forms a hydrogel.

### Claim 26 (depends on 24)

The method of claim 24, wherein the biodegradable polymers comprise hyaluronic acid polymers.

### Claim 27 (depends on 26)

The method of claim 26, wherein the hyaluronic acid polymers have a molecular weight of from about 0.1 MDa to about 10 MDa.

### Claim 28 (depends on 24)

The method of claim 24, wherein the biodegradable polymers are functionalized with cross-linking groups.

### Claim 29 (depends on 24)

The method of claim 24, wherein the biodegradable scaffold is porous and has an average pore size of from about 20 micron to about 200 micron.
